Sangani Hospital (SANGANI)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 104.50% shows strong demand or rapid capacity expansion
• Latest quarter is profitable: ₹20 crore sales and ₹1 crore net profit
• Promoter holding of 74.09% aligns management interests with minority shareholders
• Positive ROCE of 9.91% indicates the business is not destroying capital entirely

Concerns

• Profit growth is -41.52% despite huge sales growth, implying severe margin compression
• P/E of 33.31 is expensive for a company with declining profits and zero dividend yield
• Piotroski F-Score of 4/9 points to weak overall financial health
• Latest quarter net margin is only around 5%, thin for a capital-intensive hospital; debt and book value are undisclosed

AI Analysis

When I look at Sangani Hospital, I start with the price I must pay and the proof of earnings that supports it. At ₹51.40, the market cap is only ₹63 crore, so this is a very small business. The P/E of 33.31 means I am paying 33 rupees for every rupee of trailing profit. That is a demanding price, especially when reported profit growth is negative 41.52%. A company can grow sales by 104.50% and still destroy shareholder value if costs and capital needs run ahead of profits. Graham would ask: where is the margin of safety? I do not see it clearly. ROCE of 9.91% is modest for a hospital, which is typically a capital-hungry business. This return may barely clear the cost of capital, leaving little for minority shareholders. There is no dividend, so I get no cash compensation while I wait. The latest quarter shows sales of ₹20 crore and net profit of only ₹1 crore — a thin 5% net margin. That tells me expansion is happening, but it is not yet translating into durable profitability. The Piotroski F-score of 4 out of 9 reinforces my caution; this is not a financially strong business based on the numbers given. Some might point to the PEG ratio of 0.32 and call it cheap. But that ratio is only believable if the recent growth rate continues, and the actual profit trend contradicts it. I prefer a simple test: is the business earning more from the same capital over time? Right now, the answer is uncertain. Promoter holding at 74.09% is good for alignment, but it also means low liquidity. The 52-week range of ₹37 to ₹76 shows the stock can move sharply. This is not a stalwart. It is a possible turnaround, but I need proof of margin recovery, stronger returns on capital, and a better price before I commit. Buffett once said it is far better to buy a wonderful company at a fair price than a fair company at a wonderful price. Today, I am not convinced Sangani is wonderful, nor is the price clearly fair.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer